SBIR Phase I: Continuous non-invasive glucose monitor

这个小企业创新研究（SBIR）一期项目将展示一种用于糖尿病患者的新型无创血糖传感器。与脉搏血氧仪的方法类似，传感器测量表皮在两个波长上散射的光的强度，以提供敏感和特定的患者读数。S血糖浓度。这种方法将能够构建具有可穿戴形式因素（小尺寸，轻重量）和低成本的连续血糖监测仪。该装置将大大提高糖尿病患者控制血糖水平的能力，并最终支持自动闭环胰岛素输送系统（人工胰腺）。该项目的更广泛影响/商业潜力是改善数百万糖尿病患者的健康状况，降低治疗该疾病的巨大且不断增长的成本。这将通过消除反复血液检查带来的不适和提供更频繁的血糖读数来实现。糖尿病是一种无法治愈的慢性疾病。它是成年人心脏病、中风、肾功能衰竭、截肢和失明的主要原因。根据美国糖尿病协会的数据，治疗糖尿病及其并发症的直接费用约占美国医疗保健系统总费用的10%。

This Small Business Innovation Research (SBIR) Phase I project will demonstrate a new non-invasive glucose sensor for diabetes patients. Similar in approach to pulse oximetry, the sensor measures the intensity of light scattered by epidermis at two wavelengths to provide a sensitive and specific reading of the patient?s blood glucose concentration. This approach will enable the construction of a continuous glucose monitor with wearable form factors (small size, low weight) and low cost. This device will greatly improve the ability of diabetes patients to control their glucose level and eventually support an automated closed-loop insulin delivery system (artificial pancreas).The broader impact/commercial potential of this project is improvement in the health of millions of diabetes patients and reducing the large and growing cost of treating the disease. This will be achieved by eliminating the discomfort of repeated blood tests and providing more frequent glucose readings. Diabetes is a chronic disease with no cure. It is a leading cause of heart disease, stroke, kidney malfunction, amputations and blindness in the adult population. According to the American Diabetes Association, the direct cost of treating diabetes and its complications is ~10% of the entire cost of the US healthcare system.